CII
RMD icon

CR Intrinsic Investors’s ResMed RMD Stock Holding History

CR Intrinsic Investors’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-285,700
Closed -$15.1M – 346
2013
Q3 		$15.1M Buy
+285,700
New +$13.9M 0.47% 74

Other funds holding RMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

CR Intrinsic Investors's RMD Position: Q4 2013 in Review

CR Intrinsic Investors sold out of ResMed (RMD) in Q4 2013, closing a stake of 285,700 shares — an estimated $15.1M sold.

CR Intrinsic Investors first reported a position in RMD in Q3 2013 and held it in 1 quarter. The position peaked at $15.1M in Q3 2013. 328 funds tracked by Wall St. Rank hold RMD as of Q4 2013.

  • CR Intrinsic Investors reported no remaining ResMed position as of Q4 2013 after selling out during the quarter.
  • CR Intrinsic Investors sold 285,700 ResMed shares in Q4 2013, an estimated $15.1M.
  • CR Intrinsic Investors first reported a position in ResMed in Q3 2013 and held it in 1 quarter.
  • CR Intrinsic Investors's ResMed position peaked at $15.1M in Q3 2013.
  • 328 funds tracked by Wall St. Rank held ResMed as of Q4 2013.

Based on CR Intrinsic Investors's 13F filing for Q4 2013, filed 14 Feb 2014.